NASDAQ:RXRX Recursion Pharmaceuticals Q3 2024 Earnings Report $4.00 +0.04 (+0.88%) As of 10:07 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Recursion Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.33Beat/MissMissed by -$0.01One Year Ago EPS-$0.43Recursion Pharmaceuticals Revenue ResultsActual Revenue$26.08 millionExpected Revenue$12.62 millionBeat/MissBeat by +$13.46 millionYoY Revenue Growth+147.60%Recursion Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time2:30AM ETUpcoming EarningsRecursion Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Recursion Pharmaceuticals Earnings HeadlinesTempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation ModelSeptember 21 at 10:00 AM | businesswire.comIs Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?September 19 at 9:39 AM | finance.yahoo.comChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adversaries. China controls more than 90% of global rare earth processing capacity, while the U.S. imports 100% of its titanium sponge. SAGA Metals has drilled more than 23,000 meters at its Radar project, with all 92 drill holes intersecting mineralization. A maiden mineral resource estimate is expected in Q4 2026, alongside ongoing drilling at the Wolverine heavy rare earth project.September 22 at 1:00 AM | The Tomorrow Investor (Ad)Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins?September 17, 2026 | rttnews.comBicycle Therapeutics (NASDAQ:BCYC) vs. Recursion Pharmaceuticals (NASDAQ:RXRX) Head-To-Head ComparisonSeptember 17, 2026 | americanbankingnews.comRecursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comSee More Recursion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email. Email Address About Recursion PharmaceuticalsRecursion Pharmaceuticals (NASDAQ:RXRX) (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology. The company develops therapies for areas including oncology, rare diseases, and neurological disorders. Its pipeline has included investigational treatments such as REC-994 for cerebral cavernous malformation and REC-4881 for familial adenomatous polyposis, while its discovery platform is also used to evaluate additional programs and potential drug targets. Recursion works independently and through collaborations with pharmaceutical and biotechnology companies. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion has built an international technology and research presence. In 2024, the company completed a combination with Exscientia, another artificial intelligence-focused drug discovery company, expanding its capabilities in computational chemistry and therapeutic design. Recursion is led by co-founder and Chief Executive Officer Chris Gibson.View Recursion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
